Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate Cancer
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating N, Van Hemelrijck M
. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2014; 68(3):386-96.
DOI: 10.1016/j.eururo.2014.11.039.
View
2.
Lee H, McGovern K, Finkelstein J, Smith M
. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005; 104(8):1633-7.
DOI: 10.1002/cncr.21381.
View
3.
Lang R, Badano L, Mor-Avi V, Afilalo J, Armstrong A, Ernande L
. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28(1):1-39.e14.
DOI: 10.1016/j.echo.2014.10.003.
View
4.
Gong J, Payne D, Caron J, Bay C, McGregor B, Hainer J
. Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer. JACC CardioOncol. 2021; 2(4):553-563.
PMC: 8352085.
DOI: 10.1016/j.jaccao.2020.08.011.
View
5.
Imboden M, Harber M, Whaley M, Finch W, Bishop D, Kaminsky L
. Cardiorespiratory Fitness and Mortality in Healthy Men and Women. J Am Coll Cardiol. 2018; 72(19):2283-2292.
DOI: 10.1016/j.jacc.2018.08.2166.
View